CTOs on the Move

Graphite Bio

www.graphitebio.com

 
Graphite Bio is a next-generation gene editing company focused on the development of first-in-class therapies for patients suffering from life-threatening genetic diseases. The company`s platform harnesses the natural cellular process of homology directed repair (HDR) and targeted DNA integration to precisely repair genetic defects at their source. Graphite Bio is leveraging its differentiated platform to advance a portfolio of transformative genetic treatments with potential for saving and dramatically improving patients` lives
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.graphitebio.com
  • 279 East Grand Avenue Suite 430
    South San Francisco, CA USA 94080
  • Phone: n/a

Executives

Name Title Contact Details

Similar Companies

Ferre Institute

Ferre Institute is a Binghamton, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Telstar

Telstar is a Trevose, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neova Technologies

Neova Technologies Inc. is a Abbotsford, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kereos Inc

Kereos Inc is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PDL BioPharma

PDL manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. To acquire new income generating assets, PDL provides non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions, and inventors. PDL has invested approximately $780 million to date. PDL evaluates its investments based on the quality of the income generating assets and potential returns on investment. PDL is currently focused on intellectual property asset management, acquiring new income generating assets and maximizing value for its shareholders. The Company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL was founded in 1986 and is headquartered in Incline Village, Nevada. PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases for which it receives significant royalty revenue.